Head-to-head · free
U.S. Physical Therapy vs Viking Therapeutics
USPH vs VKTX — return on capital, cash generation, margins and balance sheet side by side.
USPH
3 / 4
measures where USPH leads
VKTX
1 / 4
measures where VKTX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | USPH · FY2025 | VKTX · FY2025 |
|---|---|---|
| Revenue | $781.0M | $0 |
| Net income | $39.6M | (359.6M) |
| Revenue growth (yearly, multi-year) | 12.1% | — |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | 6.0% | — |
| Return on equity | 3.1% | -47.3% |
| Gross margin | 19.2% | — |
| Operating margin | 10.3% | — |
| Net debt / EBITDA | 1.16x | 0.42x |
Figures are as reported by each company; latest fiscal year shown.
Where U.S. Physical Therapy's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Viking Therapeutics's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free